Loncar Cancer Immunotherapy ETF (CNCR)
13.95
-0.28
(-1.97%)
USD |
NASDAQ |
Apr 25, 16:00
Price Chart
Key Stats
| Net Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.79% | -0.28% | 17.22M | 41964.93 |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (Since Inception) |
| 0.00% | 86.00% | -3.407M | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks to track the performance, before fees and expenses, of the Range Cancer Therapeutics Index (the “index”). The index was established in 2023 by Range Fund Holdings and tracks the performance of a portfolio of U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts (“ADRs”) with a market capitalization of more than $250 million. The advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. Under normal circumstances, at least 80% of the fund’s total assets will be invested in the component securities of the index. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Small Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Loncar Investments |
| Prospectus Benchmark Index | |
| Range Cancer Therapeutics USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Andrew Serowik | 0.98 yrs |
| Brian Cooper | 0.98 yrs |
| Gabriel Tan | 0.98 yrs |
| Todd Alberico | 0.98 yrs |
Performance Versus Category
As of April 25, 2024. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of April 25, 2024.
Basic Info
| Investment Strategy | |
| The investment seeks to track the performance, before fees and expenses, of the Range Cancer Therapeutics Index (the “index”). The index was established in 2023 by Range Fund Holdings and tracks the performance of a portfolio of U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts (“ADRs”) with a market capitalization of more than $250 million. The advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. Under normal circumstances, at least 80% of the fund’s total assets will be invested in the component securities of the index. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Small Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Loncar Investments |
| Prospectus Benchmark Index | |
| Range Cancer Therapeutics USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Andrew Serowik | 0.98 yrs |
| Brian Cooper | 0.98 yrs |
| Gabriel Tan | 0.98 yrs |
| Todd Alberico | 0.98 yrs |